Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

According to TipRanks.com, Lutz is a 5-star analyst with an average return of 9.7% and a 60.8% success rate. Lutz covers the Healthcare sector, focusing on stocks such as Walgreens Boots Alliance, ...

Cherny covers the Healthcare sector, focusing on stocks such as Walgreens Boots Alliance, Hims & Hers Health, and Quest Diagnostics. ;'> The word on The Street in general, suggests a Moderate Buy ...

BofA analyst Allen Lutz raised the firm’s price target on Cencora (COR) to $285 from $270 and keeps a Neutral rating on the shares. The recent ...

Walgreens Cashes In: Slashes Cencora Stake Again In Debt-Fighting Move ...

Shares of Cencora Inc. COR rose 1.92% to $279.15 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 3.46% to 5,268.05 and ...

Walgreens Boots Alliance faces significant ... For example, the remaining stake in Cencora (AmerisourceBergen) is being sold for $1.3 billion, as well as the stakes in VillageMD and Boots.

Renewed collaborations with Express Scripts and Walgreens strengthen core distribution capabilities and align resources to meet customer needs effectively. Cencora operates in a highly competitive ...

Cencora, Inc. COR is well-poised for growth on the back of robust U.S. Healthcare Solutions business and product launches.

Cencora, Inc. COR is well-poised for growth on the back of robust U.S. Healthcare Solutions business and product launches. However, intense competition is a concern. Shares of this Zacks Rank #2 (Buy) ...

Last year, KFF Health News downloaded BrownGreer’s data on payouts from pharmaceutical distributors AmerisourceBergen (now called Cencora), Cardinal Health ... as well as CVS, Walgreens, and Walmart ...